D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
ESPR holding history
Esperion Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ESPR overviewAll 13F holders of ESPRFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 14
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −6,540,785−100.0% | Sold out | Holders |
| Q1 2026 | 6,540,785 | $17.9M | <0.1% | −362,698−5.3% | Reduced | Holders |
| Q4 2025 | 6,903,483 | $25.5M | <0.1% | +6,694,850+3,208.9% | Added | Holders |
| Q3 2025 | 208,633 | $552.9K | <0.1% | +208,633 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −275,707−100.0% | Sold out | Holders |
| Q1 2025 | 275,707 | $397.0K | <0.1% | +24,115+9.6% | Added | Holders |
| Q4 2024 | 251,592 | $553.5K | <0.1% | +152,019+152.7% | Added | Holders |
| Q3 2024 | 99,573 | $164.3K | <0.1% | −282,915−74.0% | Reduced | Holders |
| Q2 2024 | 382,488 | $849.1K | <0.1% | −4,760,998−92.6% | Reduced | Holders |
| Q1 2024 | 5,143,486 | $13.8M | <0.1% | +3,930,283+324.0% | Added | Holders |
| Q4 2023 | 1,213,203 | $3.63M | <0.1% | +1,213,203 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −351,039−100.0% | Sold out | Holders |
| Q3 2022 | 351,039 | $2.35M | <0.1% | −352,439−50.1% | Reduced | Holders |
| Q2 2022 | 703,478 | $4.47M | <0.1% | +66,042+10.4% | Added | Holders |
| Q1 2022 | 637,436 | $2.96M | <0.1% | −247,036−27.9% | Reduced | Holders |
| Q4 2021 | 884,472 | $4.42M | <0.1% | +861,393+3,732.4% | Added | Holders |
| Q3 2021 | 23,079 | $278.0K | <0.1% | +23,079 | New | Holders |